Copenhagen, Denmark

Jakob Ewald Rasmussen

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 16.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Copenhagen, DK (2021)
  • Koebenhavn, DK (2023)

Company Filing History:


Years Active: 2021-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Jakob Ewald Rasmussen

Introduction

Jakob Ewald Rasmussen is a notable inventor based in Copenhagen, Denmark. He has made significant contributions to the field of biochemistry, particularly in the development of glucose-sensitive compounds. With a total of two patents to his name, Rasmussen's work is recognized for its potential applications in medical science.

Latest Patents

Rasmussen's latest patents focus on glucose-sensitive albumin-binding derivatives. These inventions relate to glucose-sensitive albumin-binding diboron conjugates. More specifically, they provide novel diboron compounds, particularly diboronate or diboroxole compounds, which are useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by a specific formula, which includes a mono- to multiatomic linker. Additionally, the patents describe diboron conjugates that may carry a drug covalently attached to the diboron compound.

Career Highlights

Jakob Ewald Rasmussen is currently associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk emphasizes the importance of innovation in developing therapeutic solutions for diabetes and other chronic conditions. His contributions have been instrumental in advancing the company's research initiatives.

Collaborations

Rasmussen collaborates with esteemed colleagues such as Thomas Kruse and Mikael Kofod-Hansen. Their combined expertise fosters a productive research environment, leading to groundbreaking innovations in their field.

Conclusion

Jakob Ewald Rasmussen's work exemplifies the spirit of innovation in biochemistry. His patents on glucose-sensitive compounds hold promise for future medical applications. His contributions to Novo Nordisk further highlight the impact of collaborative research in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…